Print

Purpose

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.

Condition

Eligibility

Eligible Ages
Under 17 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • The participant must have histological or cytological evidence of a diagnosis of solid tumor, excluding lymphomas and melanoma, but including central nervous system (CNS) tumors, that is relapsed or refractory, not be amenable to curative treatment. - The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors. - The participant has a Lansky (<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50. - The participant has adequate hematologic, organ, and coagulation function ≤2 weeks (14 days) prior to first dose of study drug: - Absolute neutrophil count (ANC) ≥750 cubic millimeters (mm³) - Platelets ≥75,000/mm³ - Hemoglobin ≥8 grams per deciliter (g/dL) - Total bilirubin (sum of conjugated + unconjugated) ≤1.5 x upper limit of normal (ULN) for age - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN - Serum creatinine is based on age/gender - Adequate coagulation function as defined by International Normalized Ratio ≤1.5 or prothrombin time ≤1.5 x ULN, and partial thromboplastin time ≤1.5 x ULN - Both female and male participants of child-bearing potential must agree to use highly effective contraceptive precautions during the trial and up to 3 months following the last dose of olaratumab, or longer for other study drugs according to their label. - Participants must have fully recovered from the acute toxic effects of all prior anticancer therapies or must adhere to post-treatment conditions as follows: - Myelosuppressive chemotherapy - Hematopoietic growth factors - Biologic (anti-neoplastic agent) - Antibody therapy - Radiation - Stem cell infusion without traumatic brain injury - Corticosteroids

Exclusion Criteria

  • Have received treatment within 21 days of the initial dose of olaratumab with an investigational product or non-approved use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. - Participants that have had bone marrow or solid organ transplant are excluded. - The participant has an active fungal, bacterial, and/or known severe viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required). - Female participants who are pregnant or breastfeeding are excluded. - If the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction (LVEF < 50%) or shortening fraction of <27% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both). - Participants that have received prior anthracycline therapy if the participant is to be enrolled in the doxorubicin combination arm.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Olaratumab + Doxorubicin (Part A) 		Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Doxorubicin
    Doxorubicin administered IV.
Experimental
Olaratumab + Vincristine + Irinotecan (Part A) 		Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Vincristine
    Vincristine administered IV.
  • Drug: Irinotecan
    Irinotecan administered IV.
Experimental
Olaratumab + Ifosfamide (Part A) 		Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Ifosfamide
    Ifosfamide administered IV.
Experimental
Olaratumab + Doxorubicin (Part B) 		Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Doxorubicin
    Doxorubicin administered IV.
Experimental
Olaratumab + Vincristine + Irinotecan (Part B) 		Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Vincristine
    Vincristine administered IV.
  • Drug: Irinotecan
    Irinotecan administered IV.
Experimental
Olaratumab + Ifosfamide (Part B) 		Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Doxorubicin
    Doxorubicin administered IV.
  • Drug: Ifosfamide
    Ifosfamide administered IV.
Experimental
Olaratumab + Doxorubicin (Part C) 		Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Doxorubicin
    Doxorubicin administered IV.
Experimental
Olaratumab + Vincristine + Irinotecan (Part C) 		Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Vincristine
    Vincristine administered IV.
  • Drug: Irinotecan
    Irinotecan administered IV.
Experimental
Olaratumab + Ifosfamide (Part C) 		Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
  • Drug: Olaratumab
    Olaratumab administered IV.
    Other names:
    • LY3012207
  • Drug: Ifosfamide
    Ifosfamide administered IV.

More Details

Status
Completed
Sponsor
Eli Lilly and Company

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.

For general questions about clinical trials, contact Research Support Services at (615) 322-7343 or research.support.services@vumc.org